Form 4: Gilead Sciences CFO Andrew Dickinson Reports Stock Transactions

Andrew Dickinson, CFO of Gilead Sciences, reports transactions involving company stock, including the exercise of options and sale of shares, pursuant to a pre-arranged trading plan.

Summary

• Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, reported multiple transactions involving Gilead's common stock on March 10, 2025.
• These transactions included the exercise of non-qualified stock options to acquire 4,916 and 13,013 shares at a price of $63.91 per share.
• Dickinson also sold 4,916 shares at an average price of $117.2988 and 13,013 shares at an average price of $118.5011.
• Additionally, 7,968 restricted stock units were converted into common stock.
• A total of 3,855 shares were disposed of to cover tax obligations.
• Following these transactions, Dickinson directly owns 173,174 shares of Gilead common stock.
• Dickinson also acquired 49,020 non-qualified stock options with an exercise price of $117.21 and 11,090 restricted stock units.
• The reported transactions were made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
• The options and restricted stock units have a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the balance vesting quarterly thereafter.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, and there's no indication of any significant positive or negative implications for the company.

Positives

• The transactions are part of a pre-planned trading strategy, suggesting a structured approach to managing personal investments.
• The exercise of stock options demonstrates Dickinson's belief in the long-term value of Gilead Sciences.
• The vesting schedule of the options and restricted stock units incentivizes long-term commitment to the company.

Negatives

• The sale of shares, even under a pre-arranged plan, could be interpreted negatively by some investors, although it's a common practice for executives to diversify their holdings.

Risks

• The market's reaction to insider selling could put downward pressure on the stock price, although the existence of a 10b5-1 plan mitigates this risk.
• Changes in Gilead's performance or outlook could affect the value of Dickinson's remaining holdings.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's value and future prospects. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include stock options and restricted stock units to align management's interests with those of shareholders.
• The vesting schedules for these equity grants are typically four years, which is a standard practice in the industry.
• The use of Rule 10b5-1 trading plans is widespread among executives at publicly traded companies, including those in the pharmaceutical sector, such as Johnson & Johnson, Pfizer, and Merck.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for short-term price fluctuations.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates